Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).
Guillermo de Velasco(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Sun Young Rha(Yonsei University), Brian I. Rini(Vanderbilt University Medical Center), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Ravindran Kanesvaran(University of Ioannina), James Brugarolas(The University of Texas Southwestern Medical Center), Frede Donskov(Aarhus University Hospital), Scott North, Jae‐Lyun Lee(Ulsan College), Wanling Xie(Dana-Farber Cancer Institute), Laurence Albigès(Université Paris-Saclay), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Haru Yamamoto(University of California, Berkeley), Neeraj Agarwal(University of Utah), Reuben Broom(Auckland City Hospital), Sandhya Srinivas(Stanford Medicine), Daniel Yick Chin Heng(University of Calgary), Marina D. Kaymakcalan(Dana-Farber Cancer Institute)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k